证券代码：688217 证券简称：睿昂基因 公告编号：2025-038 上海睿昂基因科技股份有限公司 关于 2025 年半年度募集资金存放 与实际使用情况的专项报告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 根据《上市公司募集资金监管规则》和《上海证券交易所科创板股票上市规 则》《上海证券交易所科创板上市公司自律监管指引第 1 号——规范运作》等有 关规定，上海睿昂基因科技股份有限公司（以下简称"公司"或"本公司"）编制了 《2025 年半年度募集资金存放与实际使用情况的专项报告》。具体如下： 一、募集资金基本情况 （一）实际募集资金金额和资金到账时间 根据中国证券监督管理委员会《关于同意上海睿昂基因科技股份有限公司首 次公开发行股票注册的批复》（证监许可〔2021〕1126号），同意公司首次公开 发行股票的注册申请。并经上海证券交易所同意，公司首次向社会公众公开发行 人民币普通股（A股）股票1,390.00万股，本次发行价格为每股人民币18.42元， 募集资金总额为人民币25,603.80万元，扣除各项发行费用（不 ...

关于召开 2025 年半年度业绩说明会的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 会议问题征集：投资者可于 2025 年 9 月 19 日（星期五）12:00 前访问网 址 https://eseb.cn/1qL3zkmYvu0 进行会前提问，上海睿昂基因科技股份有限公司 （以下简称"公司"）将通过本次业绩说明会，在信息披露允许范围内就投资者 普遍关注的问题进行回答。 一、说明会类型 证券代码：688217 证券简称：睿昂基因 公告编号：2025-039 上海睿昂基因科技股份有限公司 五、联系人及咨询办法 联系人：周海红 电话：021-33282601 公司已于 2025 年 8 月 29 日在上海证券交易所网站（www.sse.com.cn）披露 了《上海睿昂基因科技股份有限公司 2025 年半年度报告》及《上海睿昂基因科 技股份有限公司 2025 年半年度报告摘要》。为便于广大投资者更加全面深入地 了解公司 2025 年半年度经营业绩、发展战略等情况，公司定于 2025 年 9 月 19 日 ...

证券代码：688217 证券简称：睿昂基因 公告编号：2025-040 上海睿昂基因科技股份有限公司 关于召开2025年第二次临时股东大会的通知 本公司董事会及全体董事保证公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： （五） 网络投票的系统、起止日期和投票时间。 网络投票系统：上海证券交易所股东大会网络投票系统 网络投票起止时间：自2025 年 9 月 16 日 至2025 年 9 月 16 日 一、 召开会议的基本情况 （一） 股东大会类型和届次 2025年第二次临时股东大会 召开日期时间：2025 年 9 月 16 日 14 点 00 分 召开地点：上海市奉贤区汇丰西路 1817 弄 147 号睿昂基因会议室 股东大会召开日期：2025年9月16日 本次股东大会采用的网络投票系统：上海证券交易所股东大会网络投票 系统 （二） 股东大会召集人：董事会 （三） 投票方式：本次股东大会所采用的表决方式是现场投票和网络投票相结 合的方式 （四） 现场会议召开的日期、时间和地点 采用上海证券交易所网络投票系统，通过交易系统投票平台的投票时 ...

证券代码：688217 证券简称：睿昂基因 公告编号：2025-035 上海睿昂基因科技股份有限公司 具体内容详见公司同日在上海证券交易所网站（www.sse.com.cn）披露的《上 海睿昂基因科技股份有限公司 2025 年半年度报告》及《上海睿昂基因科技股份有限 公司 2025 年半年度报告摘要》。 表决情况：同意 3 票，反对 0 票，弃权 0 票。 （二）审议通过《关于 2025 年半年度募集资金存放与实际使用情况的专项 报告的议案》 第三届监事会第四次会议决议公告 本公司监事会及全体监事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 一、监事会会议召开情况 上海睿昂基因科技股份有限公司（以下简称"公司"）第三届监事会第四次 会议于 2025 年 8 月 27 日在公司会议室以现场结合通讯方式召开，本次会议已于 2025 年 8 月 17 日以邮件方式发出会议通知。本次会议由监事会主席李云航先生 召集并主持，会议应出席监事 3 名，实际出席监事 3 名。本次会议的召集与召开 符合《中华人民共和国公司法》（以下简称"《公司法》"）等法律、 ...

证券代码：688217 证券简称：睿昂基因 公告编号：2025-037 上海睿昂基因科技股份有限公司 关于 2025 年半年度利润分配方案的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任 重要内容提示： 分配比例：每 10 股派发现金红利 1.70 元（含税），不进行公积金转增 股本，不送红股。 本次利润分配拟以上海睿昂基因科技股份有限公司（以下简称"公司"） 2025 年半年度实施权益分派股权登记日登记的总股本扣减公司回购专用证券账 户中的股份为基数分配利润，具体日期将在权益分派实施公告中明确。 如在本公告披露之日起至实施权益分派股权登记日期间，公司总股本扣 减公司回购专用证券账户中的股份数量发生变动的，公司拟维持每股分配比例不 变，相应调整分配总额。如后续总股本发生变化，将另行公告具体调整情况。 本次利润分配方案尚需提交公司 2025 年第二次临时股东大会审议。 一、利润分配方案内容 截至 2025 年 6 月 30 日，公司合并报表中未分配利润为人民币 140,339,334.45 元，母公司报表中未分配利润余额 ...

[Important Notice](index=2&type=section&id=%E9%87%8D%E8%A6%81%E6%8F%90%E7%A4%BA) This section provides critical information regarding the company's semi-annual report, including statements from governance bodies, risk warnings, and key financial decisions [Statement by Board of Directors, Supervisory Board, and Senior Management](index=2&type=section&id=%E8%91%A3%E4%BA%8B%E4%BC%9A%E3%80%81%E7%9B%91%E4%BA%8B%E4%BC%9A%E5%8F%8A%E8%91%A3%E7%9B%91%E9%AB%98%E5%A3%B0%E6%98%8E) The company's Board of Directors, Supervisory Board, and senior management guarantee the truthfulness, accuracy, and completeness of the semi-annual report content, assuming corresponding legal liabilities. The company's head, chief accountant, and head of accounting department declare the financial report is true, accurate, and complete - The company's Board of Directors, Supervisory Board, and senior management guarantee the truthfulness, accuracy, and completeness of the semi-annual report content[3](index=3&type=chunk) - Company head Gao Shangxian, chief accountant Wang Chunjuan, and head of accounting department Wang Chunjuan declare the financial report is true, accurate, and complete[6](index=6&type=chunk) [Significant Risk Warning](index=2&type=section&id=%E9%87%8D%E5%A4%A7%E9%A3%8E%E9%99%A9%E6%8F%90%E7%A4%BA) The company has detailed potential risks in the report, advising investors to refer to "Section III Management Discussion and Analysis" under "IV. Risk Factors" and be aware of investment risks - The company has described potential risks in this report; please refer to "Section III Management Discussion and Analysis" under "IV. Risk Factors"[4](index=4&type=chunk) [Absence of Directors](index=2&type=section&id=%E6%9C%AA%E5%87%BA%E5%B8%AD%E8%91%A3%E4%BA%8B%E6%83%85%E5%86%B5) Chairman Xiong Hui was unable to personally attend the board meeting due to arrest and has entrusted Gao Shangxian to attend on her behalf Absence of Directors | Position of Absent Director | Name of Absent Director | Reason for Absence | Name of Proxy | | :--- | :--- | :--- | :--- | | Chairman | Xiong Hui | Unable to personally attend due to arrest | Gao Shangxian | [Audit Status](index=2&type=section&id=%E5%AE%A1%E8%AE%A1%E6%83%85%E5%86%B5) This semi-annual report is unaudited - This semi-annual report is unaudited[6](index=6&type=chunk) [Profit Distribution Plan](index=2&type=section&id=%E5%88%A9%E6%B6%A6%E5%88%86%E9%85%8D%E9%A2%84%E6%A1%88) The company proposes to distribute a cash dividend of **RMB 1.70** (tax inclusive) per **10 shares** to all shareholders based on the total share capital on the equity registration date for the 2025 semi-annual profit distribution, with no capital reserve conversion or bonus shares. This plan is subject to shareholder approval - The company proposes to distribute a cash dividend of **RMB 1.70** (tax inclusive) per **10 shares** to all shareholders based on the total share capital registered on the equity registration date for the 2025 semi-annual profit distribution, with no capital reserve conversion or bonus shares[7](index=7&type=chunk) 2025 Semi-Annual Profit Distribution Plan | Indicator | Amount/Quantity | | :--- | :--- | | Cash Dividend per 10 Shares (incl. tax) | 1.70 RMB | | Total Share Capital (as of June 30, 2025) | 55,855,896 shares | | Number of Shares Participating in Profit Distribution | 55,186,275 shares | | Total Proposed Cash Dividend (incl. tax) | 9,381,666.75 RMB | [Forward-Looking Statement Risk Disclaimer](index=3&type=section&id=%E5%89%8D%E7%9E%BB%E6%80%A7%E9%99%88%E8%BF%B0%E7%9A%84%E9%A3%8E%E9%99%A9%E5%A3%B0%E6%98%8E) Forward-looking statements in this report regarding the company's future plans and development strategies do not constitute substantive commitments, and investors are advised to be aware of investment risks - Forward-looking statements in this report regarding the company's future plans and development strategies do not constitute substantive commitments to investors, and investors are advised to be aware of investment risks[9](index=9&type=chunk) [Section I Definitions](index=5&type=section&id=%E7%AC%AC%E4%B8%80%E8%8A%82%20%E9%87%8A%E4%B9%89) This section provides definitions of common terms used in the report, covering professional terminology to ensure accurate understanding [Definitions of Common Terms](index=5&type=section&id=%E5%B8%B8%E7%94%A8%E8%AF%8D%E8%AF%AD%E9%87%8A%E4%B9%89) This section provides definitions of common terms used in the report, covering professional terminology such as company names, subsidiaries, shareholders, in vitro diagnostic (IVD) related technologies (e.g., molecular diagnostics, immunodiagnostics, PCR, gene sequencing, FISH, ddPCR), and medical device registration classifications, ensuring accurate understanding of the report - Definitions of common terms in the report, including company, subsidiaries, shareholders, in vitro diagnostics (IVD) and its classifications, molecular diagnostics, immunodiagnostics, PCR, gene sequencing, FISH, ddPCR, and other professional terminology[14](index=14&type=chunk)[15](index=15&type=chunk) [Section II Company Profile and Key Financial Indicators](index=7&type=section&id=%E7%AC%AC%E4%BA%8C%E8%8A%82%20%E5%85%AC%E5%8F%B8%E7%AE%80%E4%BB%8B%E5%92%8C%E4%B8%BB%E8%A6%81%E8%B4%A2%E5%8A%A1%E6%8C%87%E6%A0%87) This section provides an overview of the company's basic information, contact details, stock profile, and key financial performance metrics [Company Basic Information](index=7&type=section&id=%E5%85%AC%E5%8F%B8%E5%9F%BA%E6%9C%AC%E6%83%85%E5%86%B5) Shanghai Rightongene Biomedical Technology Co., Ltd. (Rightongene) was listed on the STAR Market of the Shanghai Stock Exchange on May 17, 2021, with Xiong Hui as its legal representative, and its registered and office addresses located in Fengxian District, Shanghai Company Basic Information | Indicator | Content | | :--- | :--- | | Chinese Name | 上海睿昂基因科技股份有限公司 | | Chinese Abbreviation | 睿昂基因 | | Legal Representative | Xiong Hui | | Registered Address | Building 3, No. 6055 Jinhai Highway, Fengxian District, Shanghai | | Office Address | No. 147, Lane 1817, Huifeng West Road, Fengxian District, Shanghai | | Company Website | www.rightongene.com | [Contact Person and Information](index=7&type=section&id=%E8%81%94%E7%B3%BB%E4%BA%BA%E5%92%8C%E8%81%94%E7%B3%BB%E6%96%B9%E5%BC%8F) The company's Board Secretary (domestic representative for information disclosure) is Zhou Haihong, and the Securities Affairs Representative is Ju Kuo; contact addresses and email addresses have been disclosed Contact Person and Information | Position | Name | Contact Address | Phone | Fax | Email | | :--- | :--- | :--- | :--- | :--- | :--- | | Board Secretary (domestic representative for information disclosure) | Zhou Haihong | No. 147, Lane 1817, Huifeng West Road, Fengxian District, Shanghai | 021-33282601 | 021-37199015 | zqswb@rightongene.com | | Securities Affairs Representative | Ju Kuo | No. 147, Lane 1817, Huifeng West Road, Fengxian District, Shanghai | 021-33282601 | 021-37199015 | zqswb@rightongene.com | [Information Disclosure and Document Availability](index=7&type=section&id=%E4%BF%A1%E6%81%AF%E6%8A%AB%E9%9C%B2%E5%8F%8A%E5%A4%87%E7%BD%AE%E5%9C%B0%E7%82%B9) The company designates Shanghai Securities News, Securities Times, Securities Daily, and China Securities Journal as its information disclosure newspapers, with the semi-annual report published on the Shanghai Stock Exchange website and available at the company's Board of Directors Office - The company's selected information disclosure newspapers are Shanghai Securities News, Securities Times, Securities Daily, and China Securities Journal[19](index=19&type=chunk) - The website address for the semi-annual report is http://www.sse.com.cn/[19](index=19&type=chunk) - The company's semi-annual report is available at the company's Board of Directors Office[19](index=19&type=chunk) [Company Stock Overview](index=7&type=section&id=%E5%85%AC%E5%8F%B8%

Group 1 - The core viewpoint of the news highlights the significant increase in the stock price of Ruian Gene, which rose by 9.95% on August 26, with a trading volume of 148 million yuan [1] - On August 26, Ruian Gene had a financing purchase amount of 20.89 million yuan and a net financing purchase of 2.7854 million yuan, indicating strong investor interest [1] - As of August 26, the total balance of margin trading for Ruian Gene was 71.03 million yuan, accounting for 3.70% of its market capitalization, which is above the 80th percentile of the past year [1] Group 2 - Ruian Gene, established on February 17, 2012, specializes in the research, production, and sales of in vitro diagnostic products, primarily focusing on precision testing for blood diseases, solid tumors, and infectious diseases [2] - The company's revenue composition includes 84.71% from self-produced reagents, 8.52% from testing services, and 1.90% from research services, indicating a strong reliance on its own products [2] - For the first quarter of 2025, Ruian Gene reported a revenue of 54.738 million yuan, a year-on-year decrease of 14.72%, while its net profit attributable to the parent company was 3.355 million yuan, showing a significant increase of 529.26% [2] Group 3 - Since its A-share listing, Ruian Gene has distributed a total of 10.0541 million yuan in dividends [3] - As of March 31, 2025, the number of shareholders for Ruian Gene was 3,990, a decrease of 6.54% from the previous period, while the average circulating shares per person increased by 6.99% [2][3] - Among the top ten circulating shareholders, Huaxia CSI 500 Index Enhanced A (007994) is a new entrant, holding 531,500 shares [3]

Core Insights - The report highlights the significant compensation of CFOs in the A-share market, with a total salary scale of 4.27 billion yuan and an average annual salary of 814,800 yuan for 2024 [1] - The pharmaceutical and biotechnology sector shows a higher average CFO salary of 919,700 yuan, which is 12.8% above the overall market average [1] - In Shanghai, the average CFO salary in the pharmaceutical sector reaches approximately 1,139,100 yuan, 39.8% higher than the market average, reflecting the high operational costs and talent competition in the region [1] CFO Salary Rankings - The top ten CFOs in Shanghai's pharmaceutical sector include notable figures such as Shen Bo from Shanghai Medical with a salary of 3.054 million yuan and a growth rate of 5.75% [2] - Li Yan from Ruian Gene ranks seventh with a salary of 1.573 million yuan, marking a 15.49% increase from the previous year [2][3] Company Performance - Ruian Gene reported a total revenue of 242 million yuan for 2024, a decline of 6.16% year-on-year, and a net profit of -16 million yuan, indicating a significant downturn [4] - The company's stock price fell by 48.46%, with a market capitalization of 1.03 billion yuan by the end of 2024, alongside facing compliance penalties [5] Talent Competition - The report emphasizes the strategic importance of top-tier financial executives in high-value industries, driven by the dual factors of core regional advantages and high-value industry characteristics [5]

Market Overview - On August 1, the medical device sector rose by 0.18% compared to the previous trading day, with Lidman leading the gains [1] - The Shanghai Composite Index closed at 3559.95, down 0.37%, while the Shenzhen Component Index closed at 10991.32, down 0.17% [1] Top Gainers in Medical Device Sector - Lidman (300289) closed at 8.45, up 20.03% with a trading volume of 588,100 shares and a transaction value of 496 million yuan [1] - Rejing Bio (688068) closed at 216.50, up 11.03% with a trading volume of 44,000 shares and a transaction value of 948 million yuan [1] - Guanwu Bio (300238) closed at 19.00, up 9.20% with a trading volume of 470,900 shares and a transaction value of 878 million yuan [1] - Yingke Medical (300677) closed at 37.28, up 8.53% with a trading volume of 447,500 shares and a transaction value of 1.643 billion yuan [1] - Other notable gainers include Zhonghong Medical (300981), Sainuo Medical (688108), and Kemei Diagnosis (688468) with respective increases of 8.05%, 6.70%, and 6.66% [1] Top Losers in Medical Device Sector - Huakang Clean (301235) closed at 33.10, down 5.97% with a trading volume of 158,600 shares [2] - Kangtai Medical (300869) closed at 19.80, down 4.35% with a trading volume of 284,800 shares and a transaction value of 571 million yuan [2] - Other significant decliners include XD Chunli Medical (688236), Haooubo (688656), and Huqiang Technology (688151) with respective declines of 3.67%, 3.13%, and 3.10% [2] Capital Flow in Medical Device Sector - On the same day, the medical device sector saw a net inflow of 40.108 million yuan from institutional investors, while retail investors experienced a net outflow of 93.3185 million yuan [2][3] - Notable net inflows from institutional investors included Lepu Medical (300003) with 57.2395 million yuan and Guanwu Bio (300238) with 57.033 million yuan [3] - Conversely, significant net outflows from retail investors were observed in Lepu Medical (-82.3375 million yuan) and Guanwu Bio (-11.5 million yuan) [3]

Group 1 - TaiLong Pharmaceutical plans to apply for the registration and issuance of super short-term financing bonds not exceeding 800 million yuan, with a maturity of no more than 270 days, for purposes including replacing bank loans and supplementing working capital [1] - GuoXin Technology won a bid for a 46 million yuan automotive airbag ignition driver chip project, indicating its growing presence in the automotive semiconductor market [1] - GuoMai Technology expects a net profit increase of 60.52% to 100.33% for the first half of 2025, with a projected net profit of 125 million to 156 million yuan [2] Group 2 - ChangAluminum's subsidiary signed a 165 million yuan contract for the customized construction of a clinical and industrial base for a vaccine project, highlighting its involvement in the biopharmaceutical sector [3] - ZhongSalt Chemical acquired exploration rights for natural soda ash in Inner Mongolia for 929,000 yuan, expanding its resource base [4] - Six Kingdom Chemical announced the resignation of its deputy general manager, which may impact its operational strategy [5][6] Group 3 - FuYuan Pharmaceutical received a drug registration certificate for Bisoprolol Amlodipine tablets, indicating its expansion in the hypertension treatment market [7][8] - GuanShi Technology's subsidiary received a government subsidy of 7 million yuan, which is 45.29% of its net profit for the previous year, enhancing its financial position [9] - XiZhong Technology plans to repurchase shares worth between 75 million and 150 million yuan, aimed at employee stock ownership plans or equity incentives [10] Group 4 - BeiLu Pharmaceutical's subsidiary received approval for the raw material drug Iopromide, which is used as a contrast agent for various imaging examinations [12] - HongHui New Materials obtained a patent for a water-based protective paint for hardware parts, enhancing its product portfolio [13] - BoJi Pharmaceutical's subsidiary received two patents related to high bioavailability formulations, indicating innovation in biopharmaceutical technology [14] Group 5 - ChengJian Development received a cash dividend of 23.625 million yuan from its investment in Huaneng Capital, contributing to its investment income [15] - JiuZhou Pharmaceutical's subsidiary received a drug registration certificate for Sildenafil Citrate orally disintegrating tablets, expanding its product offerings in the erectile dysfunction treatment market [16] - RuiAng Gene's subsidiary received a government subsidy of 176,290 yuan, supporting its operational activities [17] Group 6 - FengFan Technology plans to acquire 100% equity of a subsidiary for 48 million yuan, indicating strategic expansion in the renewable energy sector [18] - AoJing Medical's subsidiary received a medical device production license, allowing it to manufacture absorbable surgical dressings [19] - TaiLin Bio's subsidiary won land use rights for an industrial site, facilitating its high-performance filter project [20] Group 7 - KaiPu Bio received a patent for a method and device for analyzing genomic copy number variations, enhancing its capabilities in molecular diagnostics [21] - Shanghai KaiBao received a drug registration certificate for Phlegm-Heat Clearing Capsules, which can be used in the treatment of COVID-19 symptoms [23] - TuoJing Life received two patents for high uniformity streptavidin applications, improving its diagnostic product stability [25] Group 8 - AnKe Bio's AK2024 injection received approval for clinical trials, marking a significant advancement in cancer treatment [26] - HuanYuan Pharmaceutical expects a net profit of 142 million to 160 million yuan for the first half of 2025, reflecting substantial growth [27] - JinHongShun terminated a major asset restructuring plan due to a lack of consensus among parties involved, impacting its strategic direction [28] Group 9 - HeZhan Energy signed a 177 million yuan contract for the sale of steel-concrete tower structures, indicating strong demand in the renewable energy sector [29] - InSai Group's acquisition plan for an 80% stake in ZhiZheTongXing was accepted by the Shenzhen Stock Exchange, indicating growth in its consulting business [30] - JiuDian Pharmaceutical received a drug registration certificate for Zinc Granules, enhancing its product line in gastrointestinal treatments [32] Group 10 - GuoYao Modern plans to publicly transfer a 51% stake in its subsidiary to optimize resource allocation [34] - GuoYao Modern's subsidiary received a drug registration certificate for Perindopril Indapamide tablets, expanding its hypertension treatment portfolio [36] - ZhongGong International signed a 175 million yuan engineering consulting service contract, showcasing its capabilities in project management [38] Group 11 - China Railway won contracts worth approximately 5.343 billion yuan for overseas construction projects, indicating its strong international presence [39] - JunPu Intelligent signed a framework contract for humanoid robot sales worth about 28.25 million yuan, reflecting growth in the robotics sector [41] - Sinopec's chairman resigned due to age, which may lead to changes in corporate governance [42] Group 12 - JiuFeng Energy's controlling shareholder plans to reduce their stake by up to 0.71%, indicating potential changes in ownership structure [44] - Zhejiang Oriental's subsidiary plans to establish a 1.74 billion yuan equity investment fund, focusing on strategic emerging industries [46] - ChenGuang New Materials received a government subsidy of 26 million yuan, significantly impacting its financial performance [48]